News Release

ADI welcomes results from significant drug trial for Alzheimer’s Disease

Toronto, 27 July 2016

  • LMTM first phase III drug trial for Alzheimer's in more than decade to show significant results
  • First drug that targets tau protein, one of two major components of Alzheimer’s pathology
  • There is a new case of dementia every 3 seconds - 2/3 will have Alzheimer's disease.
  • Further research is needed to get a better understanding of possible treatments

Alzheimer’s Disease International (ADI) welcomes the announcement of Phase 3 clinical trial results today that suggest a limited beneficial effect on key measures of Alzheimer’s Disease of the drug LMTM by TauRx Therapeutics.

The announcement was made during the penultimate day of the Alzheimer’s Association International Conference (AAIC) in Toronto, marking an important moment in the development of new treatments for Alzheimer’s disease.

The TRx-237-015 study is the first phase III drug trial for Alzheimer’s in many years to show significant results. The trial failed to show any benefit in the primary analysis, but there were interesting results in a subset of subjects with mild or moderate forms of the disease who were treated with LMTM as their only Alzheimer’s disease medication. LMTM is the first drug that targets tau protein, one of the two major components of Alzheimer's disease pathology.

There are 47 million people living with dementia worldwide, of whom 60-70% are living with Alzheimer’s Disease. Many individuals with the disease remain undiagnosed and do not receive any treatment.

Results of the study were presented at the conference by Dr Serge Gauthier CM, MD, FRCPC, Chair of the ADI Medical and Scientific Advisory Board and Director of the Alzheimer’s Disease Research Unit, McGill University, Canada.

Dr Gauthier said, “As a practicing clinician I see Alzheimer’s patients, their families and care-givers every day, and continually share their desperate need for a truly therapeutic product as today we only have symptomatic treatments available to us.

In a field that has been plagued by consistent failures of novel drug candidates in late-stage clinical trials and where there has been no practical therapeutic advance for over a decade, I am excited about the promise of LMTM as a potential new treatment option for these patients.”

Results of a second study to be published later this year are expected to confirm the potential of LMTM as a possible new monotherapy for Alzheimer's. ADI urges that further research is needed to get a better understanding of the role of new drugs, including potential disease modifying treatments.

Notes to Editors

For further information visit:

About Alzheimer’s Disease International (ADI)

ADI is the international federation of 85 Alzheimer associations around the world, in official relations with the World Health Organization. ADI's vision is an improved quality of life for people with dementia and their families throughout the world. ADI believes that the key to winning the fight against dementia lies in a unique combination of global solutions and local knowledge. As such, it works locally, by empowering Alzheimer associations to promote and offer care and support for people with dementia and their carers, while working globally to focus attention on dementia and campaign for policy change from governments. For more information, visit